BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cianci R, Montalto M, Pandolfi F, Gasbarrini GB, Cammarota G. Third-line rescue therapy for Helicobacter pylori infection. World J Gastroenterol 2006; 12(15): 2313-2319 [PMID: 16688818 DOI: 10.3748/wjg.v12.i15.2313] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 31] [Article Influence: 1.4] [Reference Citation Analysis]
Number Citing Articles
1 Lee SK, Lee SW, Park JY, Kwon BS, Kim SY, Hyun JJ, Kim JH, Jung SW, Koo JS, Yim HJ. Effectiveness and safety of repeated quadruple therapy in Helicobacter pylori infection after failure of second-line quadruple therapy: repeated quadruple therapy as a third-line therapy. Helicobacter. 2011;16:410-414. [PMID: 21923688 DOI: 10.1111/j.1523-5378.2011.00870.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
2 Lim HC, Lee YJ, An B, Lee SW, Lee YC, Moon BS. Rifabutin-based high-dose proton-pump inhibitor and amoxicillin triple regimen as the rescue treatment for Helicobacter pylori. Helicobacter. 2014;19:455-461. [PMID: 25231089 DOI: 10.1111/hel.12147] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 3.9] [Reference Citation Analysis]
3 Fakheri H, Bari Z, Sardarian H. A modified bismuth-containing quadruple therapy including a short course of furazolidone for Helicobacter pylori eradication after sequential therapy failure. Helicobacter. 2012;17:264-268. [PMID: 22759325 DOI: 10.1111/j.1523-5378.2012.00946.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
4 Urgesi R, Pelecca G, Cianci R, Masini A, Zampaletta C, Riccioni ME, Faggiani R. Helicobacter pylori infection: is sequential therapy superior to standard triple therapy? A single-centre Italian study in treatment-naive and non-treatment-naive patients. Can J Gastroenterol 2011;25:315-8. [PMID: 21766091 DOI: 10.1155/2011/967671] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
5 Almeida N, Romãozinho JM, Donato MM, Luxo C, Cardoso O, Cipriano MA, Marinho C, Sofia C. Triple therapy with high-dose proton-pump inhibitor, amoxicillin, and doxycycline is useless for Helicobacter pylori eradication: a proof-of-concept study. Helicobacter 2014;19:90-7. [PMID: 24506175 DOI: 10.1111/hel.12106] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
6 Gómez-burgaz M, García-ochoa B, Torrado-santiago S. Chitosan–carboxymethylcellulose interpolymer complexes for gastric-specific delivery of clarithromycin. International Journal of Pharmaceutics 2008;359:135-43. [DOI: 10.1016/j.ijpharm.2008.03.042] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
7 Jones KR, Cha JH, Merrell DS. Who’s Winning the War? Molecular Mechanisms of Antibiotic Resistance in Helicobacter pylori. Curr Drug ther. 2008;3:190-203. [PMID: 21765819 DOI: 10.2174/157488508785747899] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
8 Boehnke KF, Valdivieso M, Bussalleu A, Sexton R, Thompson KC, Osorio S, Novoa Reyes I, Crowley JJ, Baker LH, Xi C. Antibiotic resistance among Helicobacter pylori clinical isolates in Lima, Peru. Infect Drug Resist 2017;10:85-90. [PMID: 28331349 DOI: 10.2147/IDR.S123798] [Cited by in Crossref: 18] [Cited by in F6Publishing: 5] [Article Influence: 3.6] [Reference Citation Analysis]
9 Farzi N, Yadegar A, Sadeghi A, Asadzadeh Aghdaei H, Marian Smith S, Raymond J, Suzuki H, Zali MR. High Prevalence of Antibiotic Resistance in Iranian Helicobacter pylori Isolates: Importance of Functional and Mutational Analysis of Resistance Genes and Virulence Genotyping. J Clin Med. 2019;8. [PMID: 31744181 DOI: 10.3390/jcm8112004] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
10 Gisbert JP. “Rescue” regimens after Helicobacter pylori treatment failure. World J Gastroenterol 2008; 14(35): 5385-5402 [PMID: 18803350 DOI: 10.3748/wjg.14.5385] [Cited by in CrossRef: 79] [Cited by in F6Publishing: 77] [Article Influence: 5.6] [Reference Citation Analysis]
11 Karczewska E, Klesiewicz K, Skiba I, Wojtas-bonior I, Sito E, Czajecki K, Zwolińska-wcisło M, Budak A. Variability in Prevalence of Helicobacter pylori Strains Resistant to Clarithromycin and Levofloxacin in Southern Poland. Gastroenterology Research and Practice 2012;2012:1-7. [DOI: 10.1155/2012/418010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
12 Buzás GM, Józan J. Nitrofuran-based regimens for the eradication of Helicobacter pylori infection. J Gastroenterol Hepatol. 2007;22:1571-1581. [PMID: 17845685 DOI: 10.1111/j.1440-1746.2007.05082.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 2.1] [Reference Citation Analysis]
13 Damanhuri NS, Kumolosasi E, Omar MS, Razak AFA, Mansor AH. The influence of P-glycoprotein expression in the standard treatment of Helicobacter pylori infection in Sprague Dawley rats. Daru 2021;29:13-22. [PMID: 33405191 DOI: 10.1007/s40199-020-00377-2] [Reference Citation Analysis]
14 Nishizawa T, Suzuki H, Hibi T. Quinolone-Based Third-Line Therapy for Helicobacter pylori Eradication. J Clin Biochem Nutr. 2009;44:119-124. [PMID: 19308265 DOI: 10.3164/jcbn.08-220r] [Cited by in Crossref: 37] [Cited by in F6Publishing: 26] [Article Influence: 2.8] [Reference Citation Analysis]
15 Suknuntha K, Tantishaiyakul V, Worakul N, Taweepreda W. Characterization of muco- and bioadhesive properties of chitosan, PVP, and chitosan/PVP blends and release of amoxicillin from alginate beads coated with chitosan/PVP. Drug Dev Ind Pharm 2011;37:408-18. [PMID: 21446828 DOI: 10.3109/03639045.2010.518149] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 2.6] [Reference Citation Analysis]
16 Matsuzaki J, Suzuki H, Tsugawa H, Nishizawa T, Hibi T. Homology model of the DNA gyrase enzyme of Helicobacter pylori, a target of quinolone-based eradication therapy. J Gastroenterol Hepatol. 2010;25 Suppl 1:S7-S10. [PMID: 20586870 DOI: 10.1111/j.1440-1746.2010.06245.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
17 Zhou Q, Zhu LL, Yan XF, Pan WS, Zeng S. Drug utilization of clarithromycin for gastrointestinal disease treatment. World J Gastroenterol 2008; 14(39): 6065-6071 [PMID: 18932287 DOI: 10.3748/wjg.14.6065] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
18 Giordano A, Cito L. Advances in gastric cancer prevention. World J Clin Oncol 2012; 3(9): 128-136 [PMID: 23061031 DOI: 10.5306/wjco.v3.i9.128] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
19 Jeong MH, Chung JW, Lee SJ, Ha M, Jeong SH, Na S, Na BS, Park SK, Kim YJ, Kwon KA. [Comparison of rifabutin- and levofloxacin-based third-line rescue therapies for Helicobacter pylori]. Korean J Gastroenterol. 2012;59:401-406. [PMID: 22735872 DOI: 10.4166/kjg.2012.59.6.401] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
20 Urgesi R, Cianci R, Riccioni ME. Update on triple therapy for eradication of Helicobacter pylori: current status of the art. Clin Exp Gastroenterol. 2012;5:151-157. [PMID: 23028235 DOI: 10.2147/ceg.s25416] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
21 Spurnic AR, Bukumiric Z, Jevtovic D, Brmbolic B, Pekmezovic T, Salemovic D, Pesic Pavlovic I, Milosevic I, Ranin J, Korac M. Helicobacter pylori infection rates in dyspeptic Serbian HIV-infected patients compared to HIV-negative controls. PLoS One 2021;16:e0248041. [PMID: 33690620 DOI: 10.1371/journal.pone.0248041] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Hleba L, Charousova I, Cisarova M, Kovacik A, Kormanec J, Medo J, Bozik M, Javorekova S. Rapid identification of Streptomyces tetracycline producers by MALDI-TOF mass spectrometry. Journal of Environmental Science and Health, Part A 2018;53:1083-93. [DOI: 10.1080/10934529.2018.1474581] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
23 Karczewska E, Wojtas-Bonior I, Sito E, Zwolińska-Wcisło M, Budak A. Primary and secondary clarithromycin, metronidazole, amoxicillin and levofloxacin resistance to Helicobacter pylori in southern Poland. Pharmacol Rep 2011;63:799-807. [PMID: 21857091 DOI: 10.1016/s1734-1140(11)70592-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
24 Cattoir V, Nectoux J, Lascols C, Deforges L, Delchier JC, Megraud F, Soussy CJ, Cambau E. Update on fluoroquinolone resistance in Helicobacter pylori: new mutations leading to resistance and first description of a gyrA polymorphism associated with hypersusceptibility. Int J Antimicrob Agents. 2007;29:389-396. [PMID: 17303392 DOI: 10.1016/j.ijantimicag.2006.11.007] [Cited by in Crossref: 67] [Cited by in F6Publishing: 76] [Article Influence: 4.5] [Reference Citation Analysis]
25 Hirata Y, Ohmae T, Yanai A, Sakitani K, Hayakawa Y, Yoshida S, Sugimoto T, Mitsuno Y, Akanuma M, Yamaji Y. Sitafloxacin resistance in Helicobacter pylori isolates and sitafloxacin-based triple therapy as a third-line regimen in Japan. Int J Antimicrob Agents. 2012;39:352-355. [PMID: 22321702 DOI: 10.1016/j.ijantimicag.2011.12.002] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
26 Chuah SK, Tsay FW, Hsu PI, Wu DC. A new look at anti-Helicobacter pylori therapy. World J Gastroenterol 2011; 17(35): 3971-3975 [PMID: 22046084 DOI: 10.3748/wjg.v17.i35.3971] [Cited by in CrossRef: 97] [Cited by in F6Publishing: 99] [Article Influence: 8.8] [Reference Citation Analysis]
27 [DOI: 10.1101/569814] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
28 Wang LH, Cheng H, Hu FL, Li J. Distribution of gyrA mutations in fluoroquinolone-resistant Helicobacter pylori strains. World J Gastroenterol 2010; 16(18): 2272-2277 [PMID: 20458765 DOI: 10.3748/wjg.v16.i18.2272] [Cited by in CrossRef: 40] [Cited by in F6Publishing: 39] [Article Influence: 3.3] [Reference Citation Analysis]
29 Olokoba AB, Obateru OA, Bojuwoye MO. Helicobacter pylori eradication therapy: A review of current trends. Niger Med J. 2013;54:1-4. [PMID: 23661891 DOI: 10.4103/0300-1652.108884] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
30 Silvan JM, Gutiérrez-Docio A, Moreno-Fernandez S, Alarcón-Cavero T, Prodanov M, Martinez-Rodriguez AJ. Procyanidin-Rich Extract from Grape Seeds as a Putative Tool against Helicobacter pylori. Foods 2020;9:E1370. [PMID: 32993186 DOI: 10.3390/foods9101370] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
31 Gisbert JP. Second-line rescue therapy of helicobacter pylori infection. Therap Adv Gastroenterol. 2009;2:331-356. [PMID: 21180581 DOI: 10.1177/1756283x09347109] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]